Immunotherapy May Hold Promise for Skin Cancers After Kidney Transplant Two studies had "important differences," but can help guide clinicians Feb 13, 2024
Smoking Tied to Increased Mortality From Early-Stage Melanoma Association only see among current smokers, however Feb 06, 2024
FDA Clears AI-Powered Non-Invasive Skin Cancer Detector Intended for use in primary care, handheld device is first of its kind Jan 17, 2024
Futile Immunotherapy for Cancer Grows More Common Occurs most often at non-academic and low-volume centers Jan 04, 2024
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease Oct 25, 2023
Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years And early ctDNA reductions correlated with survival Oct 21, 2023
What to Know About Merkel Cell Carcinoma, the Rare Cancer That Killed Jimmy Buffett An expert weighs in on what to know about the uncommon skin cancer Sep 06, 2023
Jill Biden Has COVID; BA.2.86 Less Evasive Than Feared? Jimmy Buffett's Fatal Cancer Health news and commentary from around the Web gathered by ทฌวัษ็ว๘app staff Sep 05, 2023
Gut Microbiome Study Yields Clues to Melanoma Development, Progression Differences between patients and volunteers, early- vs late-stage may help guide management Aug 31, 2023
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option Aug 29, 2023
Mohs Surgery Best for Early-Stage Merkel Cell Carcinoma? Retrospective data suggest superior survival in pathologically confirmed node-negative disease Aug 23, 2023
FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanoma Hepzato Kit melphalan delivery system produced objective responses in 36% of patients Aug 15, 2023
Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma Absolute risk reduction of 9-10% in 1- and 2-year DFS compared with observation Jul 14, 2023
Dermatologists Hone Diagnostic Accuracy for Suspect Lesions With AI 'Collaboration' Sensitivity, specificity, mean accuracy, and AUC improved significantly with neural network input May 16, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
Responses to PD-1 Blockade Approach 90% in Rare Melanoma "One of the highest tumor response rates we've seen in any cancer," study discussant says Apr 17, 2023
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma Retifanlimab produced responses in 52% of patients with untreated unresectable disease Mar 22, 2023
Vitamin B3 Doesn't Cut Skin Cancer Risk After Organ Transplant Randomized study finds no benefit with 12 months of nicotinamide versus placebo Mar 01, 2023
Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice Dec 19, 2022
Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytes Almost a third of patients had objective responses, which deepened over time, study showed Nov 16, 2022
Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Response Encouraging activity with antibiotic-free protocol but not with vancomycin preconditioning Nov 14, 2022
Terry Bradshaw's Merkel Cell Carcinoma After beating bladder cancer, the Hall of Fame quarterback was diagnosed with a rare skin tumor Nov 10, 2022
Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
Keytruda Plus T-VEC Falls Short in Unresectable Melanoma No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
Are Skin Lesion Analyzers Ready for Prime Time? FDA panel not fully on board to reclassify computer-aided melanoma detection devices Jul 30, 2022
TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
Something Fishy About Tuna and Melanoma Risk Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
